Status:
ACTIVE_NOT_RECRUITING
Precision PCI Registry
Lead Sponsor:
University of Florida
Collaborating Sponsors:
University of North Carolina, Chapel Hill
National Heart, Lung, and Blood Institute (NHLBI)
Conditions:
Coronary Artery Disease
Percutaneous Coronary Intervention
Eligibility:
All Genders
18+ years
Brief Summary
The feasibility and clinical benefit of using a patient's genotype to guide antiplatelet therapy prescribing has been demonstrated. However, a more precise understanding of who to genotype, what to in...
Detailed Description
Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 receptor inhibitor (clopidogrel, prasugrel, or ticagrelor) is the standard of care after percutaneous coronary intervention (PCI) to reduce th...
Eligibility Criteria
Inclusion
- Inclusion Criteria
- Age ≥18 years
- Underwent percutaneous coronary intervention for any indication
- Had clinical CYP2C19 genotyping
- Treated with dual antiplatelet therapy including clopidogrel, prasugrel, or ticagrelor plus aspirin or
- Treated with a combination of a P2Y12 inhibitor i.e. clopidogrel, prasugrel or ticagrelor plus an oral anticoagulant.
- Exclusion Criteria:
- Managed surgically
- Treated with thrombolysis within 48 hours
Exclusion
Key Trial Info
Start Date :
July 17 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2025
Estimated Enrollment :
1643 Patients enrolled
Trial Details
Trial ID
NCT06143709
Start Date
July 17 2020
End Date
December 1 2025
Last Update
August 1 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Florida
Gainesville, Florida, United States, 32609